Zhejiang Jiuzhou Pharmaceutical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yi Jiang Mei

Chief Executive Officer (CEO)

CN¥3.6m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	6.2yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4yrs
Promedio de permanencia en la Junta Directiva	5.1yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Yi Jiang Mei (49 yo)

6.2yrs

Permanencia

CN¥3,615,000

Compensación

Mr. Yi Jiang Mei serves as Director at Zhejiang Jiuzhou Pharmaceutical Co., Ltd. since September 06, 2018, serves as its President and served as its Deputy General Manager.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yi Jiang Mei	President & Director	no data	CN¥3.62m	0.11% CN¥ 15.1m
Yujie Sha	Financial Manager	3.5yrs	CN¥1.01m	0.024% CN¥ 3.2m
Huilu Lin	VP, Secretary of the Board of Directors & Director	no data	CN¥1.58m	1.94% CN¥ 258.0m
Yuanqiang Li	Vice President	no data	CN¥1.84m	0.016% CN¥ 2.1m
Nonggang Yang	Vice President	4yrs	CN¥1.35m	0.010% CN¥ 1.4m
Minxia Huang	Vice President	4yrs	CN¥1.05m	0.010% CN¥ 1.4m
Gong Chen	Vice President	no data	CN¥2.27m	0.0013% CN¥ 176.6k

4.0yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 603456 se considera experimentado (4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yi Jiang Mei	President & Director	6.2yrs	CN¥3.62m	0.11% CN¥ 15.1m
Yujie Sha	Financial Manager	3.5yrs	CN¥1.01m	0.024% CN¥ 3.2m
Huilu Lin	VP, Secretary of the Board of Directors & Director	10yrs	CN¥1.58m	1.94% CN¥ 258.0m
Lirong Hua	Chairman	10yrs	CN¥2.51m	3.55% CN¥ 470.9m
Meng Sheng Sun	Chairman of Supervisory Board	10yrs	sin datos	sin datos
Xiao Hui Hua	Director	10yrs	sin datos	sin datos
Jicheng Li	Independent Director	4yrs	CN¥160.00k	sin datos
Biao Yu	Independent Director	4yrs	CN¥160.00k	sin datos
Ming Xu	Director	less than a year	CN¥13.30k	sin datos
Qi Jiang	Independent Director	1.3yrs	CN¥65.60k	sin datos

5.1yrs

Permanencia media

52.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 603456 se considera experimentada (5.1 años de antigüedad promedio).

Zhejiang Jiuzhou Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.39 in 3Q 2023)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 17%

Frontage Laboratories (Shanghai) Co. Ltd. agreed to acquire remaining 25% stake in Frontage Laboratories (Suzhou) Co.,Ltd. from Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) for CNY 19.6 million.

Second quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.38 in 2Q 2023)

Dividend of CN¥0.50 announced

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2024 Results on Aug 27, 2024

Now 22% overvalued

Now 21% overvalued

Now 20% undervalued after recent price drop

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2024

Full year 2023 earnings released: EPS: CN¥1.16 (vs CN¥1.11 in FY 2022)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024

Now 24% overvalued

Investor sentiment improves as stock rises 17%

Now 23% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 09, 2024

Third quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.34 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.31 in 2Q 2022)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.25 in 1Q 2022)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.24 in 3Q 2021)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) announces an Equity Buyback for CNY 100 million worth of its shares.

Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it expects to receive CNY 2.5 billion in funding

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.22 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.22 in 2Q 2021)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) signed Investment Agreement to acquire a 25.8% stake in Nan Jing Kang Chuan Ji Pharmatech Co., Ltd. from Yin Laisheng for CNY 40 million.

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.14 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.04 in 1Q 2020)

Investor sentiment deteriorated over the past week

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad